Overall survival (OS) · newly‐diagnosed EOC
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).
1 finding from 1 review
QoL · newly‐diagnosed EOC
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher proportion of patients whose hearing is improved compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
1 finding from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
no estimate extracted
44 participants
Very low
Change in weight (kg) · adults and children with cystic fibrosis
2 findings from 1 review
Change in weight z score · adults and children with cystic fibrosis
2 findings from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
Increase in appetite (subjective reporting) · adults and children with cystic fibrosis
Appetite stimulants may leads to higher increase in appetite (subjective reporting) compared with placebo (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
1 finding from 1 review
Seizure frequency reduction (3‐month blinded evaluation period) · people with drug‐resistant focal epilepsy
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
1 finding from 1 review
Adverse effects · people with drug‐resistant focal epilepsy
1 finding from 1 review